12:00 AM
Sep 27, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Northera droxidopa: Preliminary Phase III data

Top-line data from the modified intent-to-treat (mITT) population (n=160) of the double-blind, U.S. and Canadian Phase III Study 301 trial showed that Northera met the primary endpoint of significantly reducing mean composite OHQ scores from randomization to day 7 vs. placebo (1.83 vs. 0.93 points, p=0.003). The 11-point OHQ measures the severity of 6 symptoms on the orthostatic hypotension symptom assessment scale (OHSA) and 4 patient function criteria on the orthostatic hypotension daily activities scale (OHDAS). Northera also met 8 of 10 secondary endpoints by significantly improving mean scores on 4 of 6 OHSA symptoms and all 4 OHDAS symptoms vs. placebo. On the...

Read the full 498 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >